key: cord-1011965-fhy2z49t
authors: Clementi, Nicola; Criscuolo, Elena; Diotti, Roberta Antonia; Ferrarese, Roberto; Castelli, Matteo; Burioni, Roberto; Clementi, Massimo; Mancini, Nicasio
title: Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro
date: 2020-03-31
journal: bioRxiv
DOI: 10.1101/2020.03.29.014407
sha: e55d39ae871575a2fc7a64fbd9111249c1583041
doc_id: 1011965
cord_uid: fhy2z49t

While the SARS-CoV-2 pandemic is hardly hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 cells. This strongly suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.

On 11 th March 2020, WHO Director-General characterized COVID-19 as a pandemic. As of 27 th March 2020, 549,604 total cases were confirmed, accounting for 24,863 deaths 1 . To date, the clinical management of COVID-19 subjects almost exclusively consists of supportive therapy and, in particular, of ventilatory support for the most severe cases. Several drugs, some already in clinical trials, are currently being used in order to limit the inflammatory response or to hamper SARS-CoV-2 replication. Regarding the latter, no SARS-CoV-2-specific drugs are currently available and, as a consequence, there is the need for repurposing drugs used in other settings, such as chloroquine (CQ) and hydroxychloroquine (HCQ) 2, 3 . Several studies already demonstrated the in vitro efficacy of CQ and HCQ, evidencing the latter's higher activity on SARS-CoV-2 4, 5 . Importantly, a recent study also modeled the main pharmacokinetic features of HCQ trying to infer its lung concentration after different dosing regimens 6 .

It is therefore important to use this data in order to set up possible scenarios related to the real clinical use of this drug. In this study, we tested HCQ against a SARS-CoV-2 Italian clinical isolate, by using different protocols of drug administration corresponding to its possible prophylactic, therapeutic and prophylactic/therapeutic use in patients. A single HCQ concentration easily reachable in the lung and characterized by high anti-SARS-CoV-2 activity was used.

Cells, virus and antivirals. Vero E6 (Vero C1008, clone E6 -CRL-1586; ATCC) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with non-essential amino acids (NEAA), penicillin/streptomycin (P/S), Hepes buffer and 10% (v/v) Fetal bovine serum (FBS). A clinical isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489) was isolated and propagated in Vero E6 cells, and viral titer was determined by 50% tissue culture infective dose (TCID50) and plaque assay for confirming the obtained titer. All the infection experiments were performed in a biosafety level-3 (BLS-3) laboratory of Microbiology and Virology at Vita-Salute San Raffaele University, Milan, Italy. Bafilomycin A1 (BFLA) was obtained from Merck, Hydroxychloroquine (HCQ) was obtained from Sigma-Aldrich.

Virus isolation. An aliquot (0.8 mL) of the transport medium of the nasopharyngeal swab (COPAN's kit UTM® universal viral transport medium -COPAN) of a mildly symptomatic SARS-CoV-2 infected patient was mixed with an equal volume of DMEM without FBS and supplemented with double concentration of P/S and Amphotericin B. The mixture was added to 80% confluent Vero E6 cells monolayer seeded into a 25 cm 2 tissue culture flask. After 1 h adsorption at 37°C, 3 mL of DMEM supplemented with 2% FBS and Amphotericin B were added. Twenty-four hours post-infection (hpi) another 2 mL of DMEM supplemented with 2% FBS and Amphotericin B were added. Live images were acquired (Olympus CKX41 inverted phase-contrast microscopy) daily for evidence of cytopathic effects (CPE), and aliquots were collected for viral RNA extraction and In-house one-step real-time RT-PCR assay (10.1016/ S0140-6736(20)30154-9). Five days post-infection (dpi) cells and supernatant were collected, aliquoted and stored at -80°C (P1). For secondary (P2) virus stock, Vero E6 cells seeded into 25 cm 2 tissue culture flasks were infected with 0.5 mL of P1 stored aliquot, and infected cells and supernatant were collected 48 hpi and stored at -80°C. For tertiary (P3) virus stock, Vero E6 cells seeded into 75 cm 2 tissue culture flasks were infected with 1.5 mL of P2 stored aliquot and prepared as above described.

Virus titration. P3 virus stocks were titrated using both Plaque Reduction Assay (PRA, PFU/mL) and Endpoint Dilutions Assay (EDA, TCID50/mL). For PRA, confluent monolayers of Vero E6 cells were infected with 10-fold-dilutions of virus stock. After 1 h of adsorption at 37°C, the cell-free virus was removed. Cells were then incubated for 46 h in DMEM containing 2% FBS and 0.5% agarose. Cells were fixed and stained, and viral plaques were counted. For EDA, Vero E6 cells (4 × 10 5 cells/mL) were seeded into 96 wells plates and infected with base 10 dilutions of virus stock. After 1 h of adsorption at 37°C, the cell-free virus was removed, and complete medium was added to cells. After 48 h, cells were observed to evaluate CPE. TCID50/mL was calculated according to the Reed-Muench method.

Viral RNA Mini Kit following manufacturers' instructions. Reverse transcription and subsequent amplification were performed using random hexamer primers. The amplicons were sequenced on Illumina MiSeq NGS platform (Illumina, San Diego, CA, USA). Amplicon purification and quantification were performed by Agencourt AMPure XP (Beckman Coulter, Villepinte, France) and Qubit dsDNA Assay Kit (ThermoFisher Scientific, Waltham, MA, USA) respectively. Library preparation was performed by using Nextera XT DNA Library Prep Kit (Illumina, San Diego, CA, USA). The library generated was then diluted and sequenced with MiSeq Reagent Kit v2 (300-cycles) (Illumina, San Diego, CA, USA) on MiSeq platform. The quality of raw sequences obtained from MiSeq run was first checked using FastQC (v 0.11.5) (Babraham Bioinformatics). The reads were aligned on reference sequence (GISAID accession ID: EPI_ISL_412973) using BWA-mem and rescued using Samtools alignment/Map (v 1.9) and bamtoFastq. Finally, the contigs were generated using SPAdes (v 3.12.0).

Vero E6 cells (4 × 10 5 cells/mL) were seeded into 96 wells plates and treated with HCQ (10 μM) at different stages of virus infection. For full-time treatment, cells were pre-treated with the drug for 1 h prior to virus infection at 37°C, followed by virus adsorption for 1 h in the presence of the molecule. Then, cells were washed with PBS, and further cultured at 37°C with the molecule-containing medium until the end of the experiment. For pre-adsorption treatment, the agent was added to the cells for 1 h at 37°C before virus infection and maintained during virus adsorption. Then, the mixture was replaced with fresh medium without molecule till the end of the experiment. For postadsorption assays, the drug-containing medium was added to cells only after virus adsorption and maintained until the end of the experiment. Then, cells were washed with PBS, and further cultured at 37°C with the molecule-containing medium until the end of the experiment. BFLA (100 nM) was tested as control of inhibition of viral infectivity at a phagolysosome level only in a pre-adsorption treatment, alone or in combination with preadsorption HCQ treatment. Uninfected cells were included in all experimental settings to exclude possible drug-toxicity CPE. For all the experimental groups, cells were infected with 50 TCID50/mL (98 PFU/mL) SARS-CoV-2 and absorption was performed for 1h at 37°C or 4°C. Live images were acquired (Olympus CKX41 inverted phase-contrast microscopy) and cell supernatants were collected for real-time PCR (RT PCR) analysis at 72 hpi. All conditions were tested in quadruplicate.

Viral RNA extraction and real-time RT-PCR. Viral RNA was purified from 140 mL of cell culture supernatant using the QIAamp Viral RNA Mini Kit (QIAGEN), following the manufacturer's instructions. Subsequently, the purified RNA was used to perform the synthesis of first-strand cDNA, using the SuperScript™ First-Strand Synthesis System for RT-PCR (Thermo Fisher Scientific), following the manufacturer's instruction. Real-time PCR, using SYBR® Green dyebased PCR amplification and detection method, was performed in order to detect the cDNA. We used the SYBR™ Green PCR Master Mix (Thermo Fisher Scientific) the forward primer N2F: TTA CAA ACA TTG GCC GCA AA, the reverse primer N2R: GCG CGA CAT TCC GAA GAA, and the following PCR conditions: 95°C for 2 min, 45 cycles of 95°C for 20 sec, annealing at 55°C for 20 sec and elongation at 72°C for 30 sec, followed by a final elongation at 72°C for 10 min 7 . RT-PCR was performed using the ABI-PRISM 7900HT Fast Real-Time instruments (Applied Biosystems) by using optical-grade 96-well plates. Samples were run in duplicate in a total volume of 20 μL.

Statistical analysis. CPE observed for different experimental settings using HCQ and BFLA, alone or in combination, were normalized to corresponding virus infection control. RT-PCR results were analyzed calculating Delta (Δ) Ct as the difference between Ct values obtained for experimental settings and infection control. Then, two-way ANOVA and Tukey's multiple comparisons test were performed for the evaluation of Ct differences (GraphPad Prism 8).

Virus isolation and sequencing. Virus isolation was achieved after less than 72 hours. At 48 hpi the cytopathic effect (CPE) was already evident on Vero E6 cells. NGS analysis was performed by Illumina MiSeq obtaining the whole genome sequence of the cultured isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489).

The two molecules were tested using different experimental protocols, and virus adsorption was performed at both 37°C and 4°C. CPE was assessed at 72 hpi ( Fig. 1 and 2) . Virus infection positive control showed marked effects on cell morphology at 37°C as well as 4°C adsorption conditions. HCQ was effective in full-time treatment at both adsorption temperatures, and in post-adsorption treatment only when the virus was added to cells for 1 h at 4°C. The molecules did not show the same degree of protection from CPE in pre-adsorption treatment at both adsorption temperatures, as well as in post-adsorption treatment at 37°C adsorption. BFLA was tested as control of inhibition of viral infectivity at a phagolysosome level in a pre-adsorption treatment, showing full CPE protection at 37°C virus adsorption, while only partial protection was observed when the virus was added to cells at 4°C (Fig. 2) . No drug-related cytotoxic effect was observed on uninfected cells, in all experimental settings (data not shown).

Cell supernatants of different experimental settings were collected and analyzed by RT-PCR, and results confirmed CPE data analysis (Fig. 3) . In detail, a significant statistical difference of Delta Ct was observed with HCQ full-time treatment compared to infection control, both at 37°C (P < 0.05) and 4°C (P < 0.0001) virus adsorption, while HCQ post-adsorption treatment was effective (P < 0.0001) only when the virus was added to cells at 4°C. Interestingly, BFLA addition to HCQ pre-adsorption treatment resulted in a significant statistical difference of Delta Ct when compared to infection control at 37°C virus adsorption.

In the lack of SARS-CoV-2-specific drugs it is extremely important to evaluate the clinical potential of drug-repurposing in order to face the current pandemic 8 . HCQ has gained the attention of the scientific and medical community based on previous in vitro data on similar viruses (SARS and MERS) and on preliminary reports discussing its possible clinical effectiveness [2] [3] [4] . In this atypical context, in which on-field medicine often anticipates experimental laboratory pre-clinic, there is urgent need of prompt experiments addressing specific clinical questions. For example, it is not clear what is the best administration regimen to maximise possible HCQ anti-viral effectiveness in COVID-19 patients. At this regard, a recent study evaluated the direct anti-SARS-CoV-2 effect in vitro and, importantly, modelled its bioavailability at the lung level where it could maximally exert its antiviral activity. Based on a dosing regimen of 400 mg given twice daily for 1 day, followed by 200 mg twice daily for 4 more days, it also suggested the more useful drug concentrations to be used in clinicallyoriented phenotypic laboratory assays 5,6,9 . On that basis, we evaluated the HCQ antiviral activity when administered before (preadsorption), after (post-adsorption) or before and after (full-time) virus adsorption in order to simulate its possible prophylactic, therapeutic and prophylactic/therapeutic clinical use. Moreover, we focused our attention on a single concentration (10 uM) easily achieved, well tolerated and endowed with a strong antiviral activity 6 . Moreover, in order to speculate on its possible mechanism of action, we also evaluated HCQ activity performing virus adsorption at 37 and 4°C. In fact, at 37°C the virus enters the cell in a more physiological context while, conversely, at 4°C virus it can dock to the cell receptor, but its internalisation is much more limited.

In the prophylactic setting (pre-adsorption), 10uM HCQ did not interfere effectively with the viral replicative cycle neither at 37°C nor at 4°C, as evidenced in the CPE and the RT-PCR analysis. A limited antiviral activity was also observed in the therapeutic setting (postadsorption) but, interestingly, a higher HCQ antiviral activity was observed at 4°C, suggesting its predominant SARS-CoV-2 interference at the endosomal level 10, 11 . Overall, and most importantly, these results suggest a limited activity of HCQ when administered only prophylactically or therapeutically.

On the contrary, a significant antiviral activity was observed in the prophylactic/therapeutic (full-time) experimental setting both at 37°C and 4°C, as evidenced both by CPE and RT-PCR analyses. This observation allows to speculate on the need of a combined prophylactic and therapeutic clinical use of HCQ on in order to maximise its antiviral effects. In the atypical scenario of an ongoing pandemic, pre-clinical medical research should be focused on simple and fast observations potentially useful for the prompt set up of clinical trials. As an example, our observation could be easily translated in a clinical study on extremely high-risk categories, such as health care workers, based on the prophylactic administration of HCQ followed by its therapeutic use in case of positivity to SARS-CoV-2. The time is crucial during a pandemic and the correct clinical repurposing of HCQ could be really invaluable. 

An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases

Double-Quencher Probes Improved the Detection Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by One-Step RT-PCR. medRxiv

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Insights from nanomedicine into chloroquine efficacy against COVID-19